Phase 3 study for people with Lung Cancer

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Revolution Medicines, Inc.
Registry number NCT06881784
Started 6 May 2025 Today 16 October 2026 Estimated completion 1 December 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Blacktown Medical Oncology Research, Blacktown Hospital Blacktown NSW Recruiting
Blacktown Medical Oncology Research Blacktown NSW Recruiting
Chris O'Brien Lifehouse Camperdown NSW Recruiting
St. George Private Hospital Clinical Trials Unit Kogarah NSW Recruiting
Calvary Mater Newcastle Waratah NSW Recruiting
Mater Misericordiae Limited South Brisbane QLD Recruiting
Alfred House Melbourne VIC Recruiting
Sir Charles Gairdner Hospital Perth WA Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 590

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* At least 18 years old and has provided informed consent.

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

* Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.

* Measurable disease per RECIST v1.1.

* Adequate organ function (bone marrow, liver, kidney, coagulation).

* One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy.

* Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).

* Able to take oral medications.

Exclusion Criteria:

* Prior therapy with direct RAS-targeted therapy or docetaxel.

* Untreated central nervous system (CNS) metastases.

* Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).

* Ongoing anticancer therapy.

* Pregnant or breastfeeding.

Dates on the record

Started 6 May 2025
Estimated completion 1 December 2027
Registry last updated 29 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 29 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.